|
Market Cap | 47.54M | EPS (ttm) | -0.24 |
P/E | - | EPS this Y | 32.35% |
Forward P/E | - | EPS next Y | -10.87% |
PEG | - | EPS past 5Y | -37.43% |
P/S | 16.06 | EPS next 5Y | - |
P/B | 6.21 | EPS Q/Q | 12.09% |
Dividend | - | Sales Q/Q | -54.86% |
Insider Own | 30.19% | Inst Own | 15.66% |
Insider Trans | 0.00% | Inst Trans | -2.44% |
Short Float | 0.92% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 7.50 |
Avg Volume | 21.97K | 52W Range | 1.19 - 2.40 |
|
|
|
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL. |
|
|
|
Market Cap | 129.36M | EPS (ttm) | -0.45 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 3.31 | EPS next 5Y | - |
P/B | 6.14 | EPS Q/Q | -1443.33% |
Dividend | - | Sales Q/Q | -29.95% |
Insider Own | 28.31% | Inst Own | 38.54% |
Insider Trans | 21.00% | Inst Trans | 49.27% |
Short Float | 4.48% | Earnings | Mar 28/a |
Analyst Recom | - | Target Price | - |
Avg Volume | 46.68K | 52W Range | 4.61 - 13.25 |
|
|
|
Empire Petroleum Corp. engages in the exploration and development of oil and natural gas. The company possesses long-life, low operational cost, mature, producing assets with slow decline profiles in the Permian Basin, Bakken region and central Gulf Coast region, in the states of New Mexico, North Dakota, Montana, Louisiana, and Texas. Empire focuses on economical well rehabilitation, stimulation, field maintenance and management to generate low-risk cash flows that provides stability and growth for shareholders. The company was founded in August 1983 and is headquartered in Tulsa, OK. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Marchive Benjamin J. II | Director | Dec 29 '23 | Buy | 10.98 | 2,000 | 21,951 | 49,000 | Jan 02 06:04 PM | Energy Evolution Master Fund, | 10% Owner | Nov 29 '23 | Buy | 8.00 | 1,256,832 | 10,054,656 | 6,790,469 | Dec 01 04:44 PM | Mulacek Phil E | Director | May 31 '23 | Buy | 8.99 | 20,377 | 183,189 | 2,497,871 | Jun 01 06:12 PM | Vann J Kevin | Director | May 31 '23 | Buy | 8.96 | 3,115 | 27,910 | 3,115 | Jun 01 07:13 PM | Matschke Mason H. | Director | May 31 '23 | Buy | 9.16 | 700 | 6,412 | 393,346 | Jun 01 06:13 PM |
|
|
|
|
Market Cap | 105.33M | EPS (ttm) | -0.18 |
P/E | - | EPS this Y | 98.15% |
Forward P/E | 136.00 | EPS next Y | 266.67% |
PEG | - | EPS past 5Y | - |
P/S | 4.58 | EPS next 5Y | - |
P/B | 4.14 | EPS Q/Q | 177.47% |
Dividend | - | Sales Q/Q | -25.47% |
Insider Own | 53.41% | Inst Own | 13.37% |
Insider Trans | 0.01% | Inst Trans | -5.08% |
Short Float | 1.14% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 5.00 |
Avg Volume | 28.54K | 52W Range | 1.85 - 4.15 |
|
|
|
Forian, Inc. engages in the provision of healthcare information, analytics and technology services. The firm provides a suite of SaaS solution, as well as cannabis dispensaries. The company was founded by Max C. Wygod and Adam Dublin on October 15, 2020 and is headquartered in Newtown, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
WYGOD MARTIN J | Director | Oct 04 '23 | Buy | 2.38 | 1,700 | 4,046 | 62,783 | Oct 06 04:47 PM | WYGOD MARTIN J | Director | May 31 '23 | Buy | 2.40 | 4,789 | 11,494 | 61,083 | Jun 01 07:47 PM | WYGOD MARTIN J | Director | May 30 '23 | Buy | 2.39 | 4,565 | 10,910 | 56,294 | Jun 01 07:47 PM | WYGOD MARTIN J | Director | May 25 '23 | Buy | 2.34 | 3,000 | 7,020 | 51,729 | May 25 05:51 PM | WYGOD MARTIN J | Director | May 24 '23 | Buy | 2.35 | 1,327 | 3,118 | 48,729 | May 25 05:51 PM |
|
|
| |
|
Market Cap | 5.03M | EPS (ttm) | -21.49 |
P/E | - | EPS this Y | 72.59% |
Forward P/E | - | EPS next Y | 35.48% |
PEG | - | EPS past 5Y | 54.36% |
P/S | 6.37 | EPS next 5Y | - |
P/B | 1.29 | EPS Q/Q | 9.01% |
Dividend | - | Sales Q/Q | -27.04% |
Insider Own | 4.62% | Inst Own | 7.83% |
Insider Trans | 28.05% | Inst Trans | - |
Short Float | 13.15% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 17.13 |
Avg Volume | 310.64K | 52W Range | 4.29 - 14.44 |
|
|
|
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
ANDREEFF DANE | President and CEO | Dec 14 '23 | Buy | 8.10 | 5,000 | 40,475 | 16,512 | Dec 15 07:00 AM | ANDREEFF DANE | President and CEO | Dec 01 '23 | Buy | 6.45 | 2,006 | 12,935 | 13,685 | Dec 04 08:30 AM | ANDREEFF DANE | President and CEO | Nov 30 '23 | Buy | 6.37 | 2,000 | 12,741 | 12,551 | Dec 04 08:30 AM | ANDREEFF DANE | President and CEO | Aug 30 '23 | Buy | 7.64 | 5,000 | 38,212 | 11,420 | Aug 30 08:42 PM | ANDREEFF DANE | President and CEO | Aug 28 '23 | Buy | 6.37 | 5,078 | 32,339 | 8,774 | Aug 30 08:42 PM |
|
|
|
|
Market Cap | 35.12M | EPS (ttm) | 0.15 |
P/E | 55.93 | EPS this Y | 1400.00% |
Forward P/E | 28.77 | EPS next Y | 100.00% |
PEG | - | EPS past 5Y | - |
P/S | 2.10 | EPS next 5Y | - |
P/B | 3.75 | EPS Q/Q | 3.02% |
Dividend | - | Sales Q/Q | 10.07% |
Insider Own | 37.20% | Inst Own | 0.75% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.70% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 8.75 |
Avg Volume | 21.07K | 52W Range | 2.92 - 10.99 |
|
|
|
Intellinetics, Inc. is a holding company, which engages in the provision of document services and software solutions to private and public sectors. It operates through the Document Management and Document Conversion segments. The Document Management segment allows customers to capture and manage all documents across operations. The Document Conversion segment assists clients as a part of overall document strategy to convert documents from one medium to another, predominantly paper to digital, including migration to software solutions. The company was founded by A. Michael Chretien, Matthew L. Chretien, and Thomas D. Moss on October 3, 1997 and is headquartered in Columbus, OH. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
TAGLICH ROBERT | 10% Owner | Jun 13 '23 | Buy | 3.39 | 1,000 | 3,390 | 453,149 | Jun 15 05:30 PM |
|
|
| |
|
Market Cap | 207.41M | EPS (ttm) | -1.53 |
P/E | - | EPS this Y | -8.55% |
Forward P/E | - | EPS next Y | -41.41% |
PEG | - | EPS past 5Y | -83.05% |
P/S | 942.77 | EPS next 5Y | - |
P/B | 4.62 | EPS Q/Q | -10.45% |
Dividend | - | Sales Q/Q | -56.12% |
Insider Own | 34.90% | Inst Own | 12.80% |
Insider Trans | 0.11% | Inst Trans | -4.84% |
Short Float | 12.31% | Earnings | Mar 28/a |
Analyst Recom | 1.33 | Target Price | 19.67 |
Avg Volume | 78.18K | 52W Range | 5.87 - 14.74 |
|
|
|
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer's disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Juda Scott | Director | Nov 10 '23 | Buy | 6.95 | 7,000 | 48,650 | 37,000 | Nov 13 11:31 AM | Schroeder Timothy j | Director | Jul 12 '23 | Sale | 11.01 | 10,000 | 110,085 | 82,187 | Jul 14 04:05 PM |
|
|
|
|
Market Cap | 325.84M | EPS (ttm) | -5.18 |
P/E | - | EPS this Y | 60.78% |
Forward P/E | - | EPS next Y | 47.52% |
PEG | - | EPS past 5Y | -53.05% |
P/S | - | EPS next 5Y | 12.40% |
P/B | 1.08 | EPS Q/Q | 35.29% |
Dividend | - | Sales Q/Q | - |
Insider Own | 7.36% | Inst Own | 76.91% |
Insider Trans | 0.00% | Inst Trans | 2.83% |
Short Float | 4.16% | Earnings | Mar 28/a |
Analyst Recom | 3.00 | Target Price | 2.83 |
Avg Volume | 825.07K | 52W Range | 1.37 - 9.80 |
|
|
|
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
BORGESON JOHN A. | See Remarks | Jun 16 '23 | Sale | 9.23 | 2,749 | 25,373 | 178,077 | Jun 16 08:25 PM | EHRLICH JASON | See Remarks | Jun 16 '23 | Sale | 9.23 | 2,258 | 20,841 | 61,924 | Jun 16 08:27 PM | BORGESON JOHN A. | See Remarks | Jun 14 '23 | Sale | 9.42 | 1,448 | 13,640 | 175,332 | Jun 16 08:25 PM | EHRLICH JASON | See Remarks | Jun 14 '23 | Sale | 9.42 | 1,132 | 10,663 | 58,688 | Jun 16 08:27 PM |
|
|
| |
|
Market Cap | 6.80M | EPS (ttm) | -7.95 |
P/E | - | EPS this Y | -277.31% |
Forward P/E | - | EPS next Y | -27.55% |
PEG | - | EPS past 5Y | - |
P/S | 0.15 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -115.37% |
Dividend | - | Sales Q/Q | -10.17% |
Insider Own | 30.15% | Inst Own | 10.15% |
Insider Trans | -0.18% | Inst Trans | -36.86% |
Short Float | 2.35% | Earnings | Mar 28/a |
Analyst Recom | 2.33 | Target Price | 7.00 |
Avg Volume | 33.10K | 52W Range | 2.06 - 16.00 |
|
|
|
Leafly Holdings, Inc. operates as an online platform to buy and learn about cannabis products. The firm's Leafly database provides information on strains and contains cannabis articles and resources to education consumers. Its customer acquisition tool connects consumers to cannabis brands and licensed retailers. Leafly offers cannabis retailers and brands subscription-based marketplace listings that provide information, reviews, menus, and ordering and delivery options through legal retailers. The company was founded in 2010 and is headquartered in Seattle, WA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Miyashita Yoko | CEO | Oct 26 '23 | Sale | 6.97 | 671 | 4,680 | 28,680 | Oct 30 04:35 PM | Krishnaswamy Suresh | CFO | Oct 26 '23 | Sale | 6.97 | 489 | 3,410 | 19,963 | Oct 30 04:37 PM | Miyashita Yoko | Chief Executive Officer | Aug 23 '23 | Sale | 0.32 | 9,361 | 2,956 | 577,582 | Aug 24 04:34 PM | Krishnaswamy Suresh | Chief Financial Officer | Aug 23 '23 | Sale | 0.32 | 6,241 | 1,971 | 389,036 | Aug 24 04:33 PM | Miyashita Yoko | Chief Executive Officer | Jul 25 '23 | Sale | 0.30 | 4,032 | 1,210 | 586,943 | Jul 27 04:40 PM |
|
|
|
|
Market Cap | 105.59M | EPS (ttm) | -0.59 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -40.47% |
P/S | 2.64 | EPS next 5Y | 24.57% |
P/B | 12.41 | EPS Q/Q | -202.42% |
Dividend | - | Sales Q/Q | 501.62% |
Insider Own | 0.95% | Inst Own | 12.68% |
Insider Trans | 0.00% | Inst Trans | -4.92% |
Short Float | 2.26% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 4.50 |
Avg Volume | 1.29M | 52W Range | 1.07 - 12.78 |
|
|
|
NaaS Technology, Inc. engages in the provision of electric vehicle charging services. The firm maintains an EV charging network in China through its charging network for third-party charging station operators, and the number of public DCFCs (direct current fast charger with 30kW power output or more) connected to its network. The company was founded by Zhen Dai and Yang Wang on July 16, 2013 and is headquartered in Beijing, China. |
|
|
|
Market Cap | 9.11M | EPS (ttm) | -2.80 |
P/E | - | EPS this Y | 59.43% |
Forward P/E | - | EPS next Y | 23.78% |
PEG | - | EPS past 5Y | 34.91% |
P/S | - | EPS next 5Y | - |
P/B | 1.34 | EPS Q/Q | 62.95% |
Dividend | - | Sales Q/Q | - |
Insider Own | 1.41% | Inst Own | 1.19% |
Insider Trans | 0.00% | Inst Trans | -7.66% |
Short Float | 0.45% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 11.00 |
Avg Volume | 132.17K | 52W Range | 0.80 - 2.91 |
|
|
|
ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Thornton Michael Milos | Chief Technology Officer | May 18 '23 | Buy | 1.65 | 15,000 | 24,750 | 34,139 | May 22 07:30 AM | DIGIANDOMENICO ANTHONY | Director | May 02 '23 | Buy | 1.20 | 83,333 | 100,000 | 102,434 | May 03 04:07 PM |
|
|
|